Back to Search
BRETT IZZO, M.D.
M.D.
Cardiovascular Disease Physician
NPI: 1417210048IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
52956(TN)2018-00896(NC)
Cardiovascular Disease PhysicianPrimary
Internal Medicine — Cardiovascular Disease
Code: 207RC0000X
2018-00896(NC)
Education
STATE UNIVERSITY OF NEW YORK DOWNSTATE MEDICAL CENTER
Class of 2012
Research & Publications (18)
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia.
PMID 18508799·Haematologica·2008
3-trial
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
PMID 17692911·Leuk Res·2008
3-trial
Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype.
PMID 17036374·Hematol Oncol·2007
8-other
Presence of FLT3 mutations does not impair stem cell mobilization and feasibility of autologous peripheral blood stem cell transplantation in acute myeloid leukemia.
PMID 16920565·Biol Blood Marrow Transplant·2006
4-observational
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
PMID 17189410·Clin Cancer Res·2006
4-observational
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
PMID 16707599·Clin Cancer Res·2006
3-trial
Endocrine and ultrasonographic aspects of the oestrous cycle of the mule.
PMID 16326968·Vet Rec·2005
7-preclinical
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
PMID 15867198·J Clin Oncol·2005
3-trial
Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.
PMID 15744351·Leukemia·2005
3-trial
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia.
PMID 15319292·Blood·2004
3-trial
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.
PMID 14645009·Blood·2004
3-trial
Determination and differentiation of surface and bound water in drug substances by near infrared spectroscopy.
PMID 12712426·J Pharm Sci·2003
4-observational
BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations.
PMID 12476311·Oncogene·2002
6-review
A novel MLL/AF4 fusion gene lacking the AF4 transactivating domain in infant acute lymphoblastic leukemia.
PMID 12433702·Blood·2002
5-case
Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/Tcry5+) and DERL-7 (CD56+/CD3-/TCRgammadelta-), derived from a single patient with CD56+ non-Hodgkin's lymphoma.
PMID 11587224·Leukemia·2001
5-case
Coexistence of two distinct cell populations (CD56(+)TcRgammadelta(+) and CD56(+)TcRgammadelta(-)) in a case of aggressive CD56(+) lymphoma/leukemia.
PMID 10800166·Haematologica·2000
5-case
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 5 VANDERBILT PARK DR, ASHEVILLE CARDIOLOGY ASSOCIATES
ASHEVILLE, NC 28803 - Phone
- (828) 274-6000
Quick Facts
- NPI
- 1417210048
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 14
- Publications
- 18
Are you this provider?
Claim Your Profile